This page shows the latest Zoetis news and features for those working in and with pharma, biotech and healthcare.
unit Zoetis to deal with accretion and dilution.
Boehringer's animal health unit is now the second-largest in the business, only surpassed by Pfizer spin-out Zoetis.
The company has been deliberating a split since it span out its animal health division via an initial public offering (IPO) into stand-alone company Zoetis, and in particular had been
The veterinary sector saw Pfizer spin out its Zoetis unit - the biggest player in the market - in 2011, while Elanco bought Novartis' unit last year to claim the second spot ahead
other subsidiaries including Xellia Pharma and Zoetis Products LLC.
Boehringer, meanwhile, would become the second-largest animal health company after Pfizer spin-out Zoetis if the deal goes through, with pro forma sales of 3.8bn in 2015 putting it
More from news
Approximately 2 fully matching, plus 24 partially matching documents found.
form of Zoetis who this month acquired Abbott's animal health business for $255m. ... Bill Ackman, a Valeant investor, now owns 8.5% of Zoetis, which may pave the way for a potential deal.
spot in terms of sales, second only to Zoetis.
Several major pharma firms are deciding where to focus their business interests with Pfizer spinning out Zoetis for its animal health interests and Abbott doing the same for its pharma business,
2012. The next major event in the animal health deal calendar will probably be the IPO of Pfizer's animal health business (named in the IPO documents as Zoetis) which had
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...